![](https://news.europawire.eu/wp-content/uploads/2023/03/OncoC4-licenses-next-generation-anti-CTLA-4-monoclonal-antibody-candidate-to-BioNTech-144x144.jpg)
(IN BRIEF) Pfizer and BioNTech have received a recommendation for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. The recommendation includes the administration of a single … Read the full press release